Peptídeo derivado da lactoferricina bovina: síntese, caracterização, avaliação da atividade frente a linhagens celulares de câncer de mama e desenvolvimento preliminar de formulação lipossomal
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
DOI
Abstract
The purpose of this work was to synthesize and characterize two peptides derived
from bovine lactoferricin (26[F] LfcinB (20 – 30)2 and 26[1-NAL] LfcinB (20 – 30)2), to
evaluate the in vitro activity against breast cancer cell lines (MCF-7 and MDA-MD231) and subsequently develop a liposomal formulation for the encapsulation of the
peptide considered most promising. The peptides were obtained by solid phase
synthesis (SPPS) using the 9-fluorenylmethyloxycarbonyl/tert-butyl (Fmoc/tBu)
methodology, purified by SPE chromatography and the collected fractions were
analyzed by HPLC-FR, ESI-Q-TOF and MALDI-TOF. The purity was greater than
80% for both peptides. The HPLC-FR results showed that the retention times
obtained were similar to those reported in the literature. The ESI-MS mass spectra
showed [M+H]+ signals very close to the expected m/z ratios, which confirmed the
chemical identity of the peptides. Furthermore, molecular identification was
confirmed by MALDI-TOF/MS. The peptides were also evaluated for their influence
on the viability of tumor cells (MCF-7 and MDA-MB-231) and normal cells (CCD1059
SK) using the tetrazolium salt reduction method. In this case, the peptide 26[F] LfcinB
(20 – 30)2 showed greater selectivity against tumor cells, especially for the MDAMB-231 cell line, considered highly invasive and with high metastatic potential.
Therefore, it was chosen to continue the study. When it was evaluated the antimigratory effect (scracth assay) against tumor cell lines, this peptide showed a dosedependent effect with more pronounced inhibitory activity, also for the MDA-MB-231
cell line. Finally, conventional liposomes (Lip) were developed using a
nanoprecipitation technique for peptide encapsulation (Lip-Pep), which were
characterized by means of hydrodynamic diameter (DHm), polydispersity index,
Zeta potential (PZ), encapsulation efficiency (EE) and in vitro release profile. The
developed vesicles showed a monodisperse characteristic (PdI < 0.3). The DHm of
Lip-Pep (102.6 ± 9.91 nm) was higher than that observed for “empty” Lips (without
the addition of the peptide; Lip-B = 74.99 ± 1.32 nm), which constituted the first
indication of the occurrence of encapsulation. The EE of the peptide in the liposomes
was approximately 100%. The PZ of Lip-Pep (-22.3 ± 3.54 mV) was less negative
than that obtained for Lip-B (-32.0 ± 1.82 mV), probably due to electrostatic
interactions between the cationic peptide and the anionic phospholipid used to
prepare liposomes. This hypothesis may explain the result obtained in the in vitro
release assay, which demonstrated that there was no release of the peptide during
the 24 hours of the experiment. This behavior made further evaluation of the
formulation unfeasible. Thus, although we found promising activity of the peptide
against the MDA-MB-231 cell line, in order to continue the study it will be necessary
to develop a new liposomal formulation, possibly with a non-inonic phospholipid.
Description
Keywords
Citation
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

